# Vaccines: Supply chain

Source page: https://www.materialinsights.org/products/p_vaccines/prod-supply/

#### Output and value

World output and its value, with year and source

| Measure | Value | Unit | Year | Source |
|---|---|---|---|---|
| World market volume of vaccines (WHO report as translated into Spanish; doses) | 7 billion | doses | 2023 | ^[3] |
| Doses delivered by UNICEF to 99 countries | 2.79 billion | doses | 2024 | ^[4] |
| COVID-19 vaccines' value in the world market, 27% of the total (WHO report as translated) | 20 billion | US$ | 2023 | ^[3] |
| Serum Institute of India, doses a year by the company's own statement (self-reported, not world output) | 1.5 billion | doses a year, more than | – | ^[19] |
| Sanofi vaccine net sales (one company's sales, not output) | 7936 | EUR million | 2025 | ^[17] |
| GSK vaccine sales (one company's sales, not output) | 9.2 | GBP billion | 2025 | ^[18] |

as of 2026-11-14

#### Where it is made

Country shares of world output

| Country | Measure | Year | Source |
|---|---|---|---|
| India | The three largest Indian producers made more than 40% of the global total of vaccine output in 2024 (Statista's reading of WHO data; a lower bound, not a country share) | 2024 | ^[5] |

as of 2026-11-14

#### Main companies

The largest makers and their shares

| Company | Country | Measure | Year | Source |
|---|---|---|---|---|
| Serum Institute of India | India | Named the world's largest vaccine manufacturer by volume in Statista's reading of WHO data for 2024; the company says it makes and sells more than 1.5 billion doses a year (as repeated by DCVMN) | 2024 | ^[5]^[19] |
| Merck and Pfizer (together) | United States of America | Together more than 40% of the world market's financial value in 2024 (Statista's reading of WHO data) | 2024 | ^[5] |
| Sanofi | France | Vaccine net sales of EUR 7,936 million in 2025 (sales, not output); release dated Paris | 2025 | ^[17] |
| GSK | United Kingdom | Vaccine sales of GBP 9.2 billion in 2025 (sales, not output); release issued in London | 2025 | ^[18] |

as of 2026-11-14

#### Supply chains of the main makers

For the top three to five producing countries and India: share, where inputs and components come from, main makers and how variants differ

| Country | Inputs from | Makers | How variants differ | Year | Source |
|---|---|---|---|---|---|
| India | Not stated in the pages opened | Serum Institute of India and other makers; India has 36 major vaccine manufacturing facilities | Vaccines made in India serve the national and international market (150 countries); WHO retained India's regulator at maturity level 3 in a September 2024 review | 2024 | ^[15]^[19] |

as of 2026-11-14

#### Industries that make it

The industries and kinds of firm that make it
 Made by

- [Biologics and vaccine manufacturers](https://www.materialinsights.org/industries/pharmaceuticals/) World WHO counted 116 manufacturers of 88 vaccine products for 2023 ^[1]; as reported, the ten largest supplied 73% of doses ^[3].
- [Innovator pharma and biotech companies](https://www.materialinsights.org/industries/pharmaceuticals/) World Merck and Pfizer together took more than 40% of the market's value in 2024 ^[5]; Sanofi and GSK vaccine sales are in ^[17]^[18].

as of 2026-11-14

#### Rules and standards

Labels, efficiency and emission standards, producer responsibility, bans and tariffs

| Rule | Place | Year | What it does | Source |
|---|---|---|---|---|
| Universal Immunisation Programme: free immunisation against 12 diseases | India | 2024 | The state programme provides free immunisation against 12 diseases, nine of them nationwide, with a target of around 2.67 crore newborns and 2.9 crore pregnant women a year | ^[14] |
| WHO assessment of India's vaccine regulatory system (national regulatory authority, CDSCO) | India | 2024 | A September 2024 WHO review found that CDSCO, with the national regulatory authority and affiliated institutions, meets WHO's published indicators for a functional vaccine regulatory system; India retains maturity level 3; the functions assessed include lot release and clinical trials oversight | ^[15] |
| Bio-Medical Waste Management Rules 2016 | India | 2016 | Live or attenuated vaccines are yellow category laboratory waste that must be pre-treated by disinfection before it goes to a common treatment facility, and syringes without needles go in the red category (as set out in the Delhi government's 2025 compendium of the rules) | ^[28] |
| WHO prequalification of vaccines for UN supply | World | – | WHO assesses vaccines for UNICEF and other UN agencies that purchase vaccines, relies on the national regulator responsible for the vaccine, and audits the manufacturing site with observers from that regulator | ^[22] |
| WHO and UNICEF joint policy statement on injection safety | World | 2019 | Strongly recommends the systematic and exclusive use of auto-disable syringes for delivering vaccines | ^[11] |
| Cold chain and controlled temperature chain conditions (WHO) | World | – | Almost all vaccines are licensed for storage and distribution at 2 to 8 degrees C; a vaccine used in the controlled temperature chain must tolerate a single exposure of at least 40 degrees C for at least three days just before administration | ^[9] |

as of 2026-11-14

#### India

India's output, trade, makers and rules in a short paragraph

India's Universal Immunisation Programme gives free immunisation against 12 diseases ^[14]. India has 36 major vaccine manufacturing facilities, and its vaccines go to 150 countries ^[15]; the three largest Indian producers made more than 40% of global vaccine output in 2024, as reported from WHO data ^[5]. WHO retained India's regulator at maturity level 3 in 2024 ^[15]. No source opened gives India's output in doses, its trade values or its import shares.

as of 2026-11-14

#### Trade

World exports, the top exporters and importers and India, from UN Comtrade by HS code (worked out by the site)

| Flow | Value | Unit | Volume | Unit | Year | Source |
|---|---|---|---|---|---|---|
| World exports | 47.18 | USD billion | 63 | thousand tonnes | 2024 | UN Comtrade, HS 3002.41 |
| Average export value (calculated) | 748.36 | USD per kg | – | – | 2024 | UN Comtrade, HS 3002.41 |
| Exporter: Belgium (32.8% of world exports) | 15.46 | USD billion | 8.5 | thousand tonnes | 2024 | UN Comtrade, HS 3002.41 |
| Exporter: Ireland (17.5% of world exports) | 8.26 | USD billion | 1.3 | thousand tonnes | 2024 | UN Comtrade, HS 3002.41 |
| Exporter: United States (11.8% of world exports) | 5.56 | USD billion | 5.1 | thousand tonnes | 2024 | UN Comtrade, HS 3002.41 |
| Exporter: France (8.5% of world exports) | 4.01 | USD billion | 35.3 | thousand tonnes | 2024 | UN Comtrade, HS 3002.41 |
| Exporter: Italy (7.5% of world exports) | 3.53 | USD billion | 1.4 | thousand tonnes | 2024 | UN Comtrade, HS 3002.41 |
| India exports (rank 9, 2.3% of world) | 1.08 | USD billion | 4.5 | thousand tonnes | 2024 | UN Comtrade, HS 3002.41 |
| India imports (rank 20, 0.7% of world) | 0.34 | USD billion | 0.3 | thousand tonnes | 2024 | UN Comtrade, HS 3002.41 |
| Importer: United States (19.6% of world imports) | 9.36 | USD billion | 2.3 | thousand tonnes | 2024 | UN Comtrade, HS 3002.41 |
| Importer: Belgium (10.6% of world imports) | 5.06 | USD billion | 1.4 | thousand tonnes | 2024 | UN Comtrade, HS 3002.41 |
| Importer: China (10.2% of world imports) | 4.89 | USD billion | 1.3 | thousand tonnes | 2024 | UN Comtrade, HS 3002.41 |

Worked out from data

#### Sources

1. [Global vaccine market report 2024](https://www.who.int/publications/m/item/global-vaccine-market-report-2024) World Health Organization, 2024, landing page, published 19 December 2024; data for 2023; WHO lists a final version (B09198, 3 February 2025)
2. [Informe del mercado mundial de vacunas 2024 (Spanish translation of the WHO Global vaccine market report 2024)](https://www.saludyfarmacos.org/lang/en/boletin-farmacos/boletines/may202502/17_in) Salud y Fármacos, Boletín Fármacos, 2025, secondhand: a Spanish translation by Salud y Fármacos of the WHO report; the WHO PDFs could not be opened from this session
3. [UNICEF Supply Annual Report 2024](https://www.unicef.org/supply/reports/unicef-supply-annual-report-2024) UNICEF Supply Division, 2025
4. [Biggest vaccine manufacturers in the world by volume and financial value (chart 'Vaccine Production: Volume or Profits?', by Katharina Buchholz, data from the WHO 2025 Global Vaccine Market Report)](https://www.statista.com/chart/36423/biggest-vaccine-manufacturers-in-the-world-by-volume-and-financial-value/) Statista, 2026, secondhand: Statista's reading of WHO data for 2024; published 15 July 2026
5. [Extended Controlled Temperature Conditions (ECTC)](https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/vaccine-standardization/extended-controlled-temperature-conditions) World Health Organization
6. [Promoting the exclusive use of injection safety devices for all immunization activities](https://www.technet-21.org/media/com_resources/trl/5051/multi_upload/RUP_WU_JointStatement_FINAL_13Feb2019.pdf) World Health Organization and UNICEF (joint statement), 2019, revised 2019 joint statement (file dated 13 February 2019)
7. [World Immunization Day 2024: India's Immunization Drive: A Commitment to Universal Vaccine Coverage and Health Equity](https://static.pib.gov.in/WriteReadData/specificdocs/documents/2024/nov/doc2024119432301.pdf) Ministry of Health and Family Welfare, Government of India (PIB), 2024, 7 November 2024
8. [National Regulatory Authority of India meets WHO international standards for vaccine regulations](https://pib.gov.in/PressReleasePage.aspx?PRID=2064070) Ministry of Health and Family Welfare, Government of India (PIB), 2024, PIB Delhi, 11 October 2024
9. [Sanofi 2025 full-year results press release (Form 6-K)](https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm) Sanofi, 2026, dated Paris, January 29, 2026; Vaccines net sales table (€ million)
10. [GSK delivers strong 2025 performance and re-affirms long-term outlooks](https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/) GSK, 2026, issued London, 4 February 2026
11. [Serum Institute of India Pvt. Ltd.](https://dcvmn.org/member/siil/) Developing Countries Vaccine Manufacturers Network (DCVMN), secondhand: the company's own figures as repeated by DCVMN; no page date
12. [System for the prequalification of vaccines for UN supply](https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/vaccines-quality/vaccine-pq/prequalification-system-for-un-supply) World Health Organization
13. [Management of Healthcare Waste as per Biomedical Waste Management Rules, 2016: A Compendium of Resources 2025](https://dpcc.delhi.gov.in/sites/default/files/DPCC/generic_multiple_files/finalised-bmw-bookpagenumberpdf-386700f3867e507cfae009196f9a8629.pdf) Department of Environment, Government of NCT of Delhi, with the Centre for Occupational and Environmental Health, 2025, Table 1 (categories of biomedical waste), pp. 3 and 4, and section 3.1

## Other sections

- [Summary](https://www.materialinsights.org/products/p_vaccines/index.md)
- [Working](https://www.materialinsights.org/products/p_vaccines/prod-working/index.md)
- [Bill of materials](https://www.materialinsights.org/products/p_vaccines/prod-bom/index.md)
- [Use case](https://www.materialinsights.org/products/p_vaccines/prod-use/index.md)
- [Footprint](https://www.materialinsights.org/products/p_vaccines/prod-footprint/index.md)
- [Evolution](https://www.materialinsights.org/products/p_vaccines/prod-evolution/index.md)
- [Interventions](https://www.materialinsights.org/products/p_vaccines/prod-interventions/index.md)
